Last updated: March 9, 2026
What is the drug associated with NDC 65162-0890?
The NDC 65162-0890 corresponds to Voretigene Neparvovec (Luxturna), a gene therapy approved by the FDA in December 2017 for treating RPE65-mediated inherited retinal disease. It is used specifically for patients with confirmed biallelic RPE65 mutation-associated vision loss.
How large is the market for Voretigene Neparvovec?
Current Patient Population
- Estimated eligible patients in the U.S.: approximately 2,000.
- Global population estimate: approximately 10,000, considering varying genetics and approval statuses.
Market Penetration
- As of 2023, approximately 15-20% of eligible patients have received the therapy.
- The adoption rate is limited by high cost, specialty administration requirements, and diagnostic complexities.
Competitive Landscape
- No direct gene therapy competitors.
- Conventional treatment options are limited to low-vision aids and supportive care, with no curative therapies available.
Market Drivers
- Rising awareness and improved diagnostic testing.
- Expansion of clinical indications, including milder phenotypes.
- Geographic expansion beyond the U.S., including Europe and Asia.
Price history and current pricing
- Initial launch price (2017): $425,000 per eye, or $850,000 for the full treatment.
- Current average price (2023): $425,000 per eye; pricing has remained stable post-launch, with some regional adjustments.
Pricing considerations
- The high upfront cost reflects manufacturing complexities, regulatory hurdles, and one-time treatment nature.
- Payers are increasingly demanding outcome-based agreements due to the high initial expense.
Price projections (2023-2028)
| Year |
Estimated Patient Uptake |
Expected Pricing |
Revenue Projections |
| 2023 |
300-600 patients |
$425,000 per eye |
$255M-$510M |
| 2024 |
700-1,200 patients |
$425,000 per eye |
$595M-$1.02B |
| 2025 |
1,200-1,800 patients |
$425,000 per eye |
$1.02B-$1.53B |
| 2026 |
1,800-2,200 patients |
$425,000 per eye |
$1.53B-$1.87B |
| 2027 |
2,200-2,500 patients |
$425,000 per eye |
$1.87B-$2.12B |
Market growth factors
- Increasing diagnosis rates due to better genetic testing.
- Expanded approvals in Europe and Asia starting 2024.
- Potential downward pressure from biosimilar or alternative gene therapies.
Cost considerations and potential price adjustments
- Payers may negotiate discounts or outcome-based agreements.
- Future innovations may reduce manufacturing costs, influencing price decline.
Regulatory and reimbursement landscape
- FDA approved in 2017; EMA approved in 2020.
- Reimbursement by Medicare, private insurers, and national health services varies.
- Payer pressure prompts outcome-based reimbursement models, influencing effective price.
Key challenges influencing future pricing
- High manufacturing costs.
- Limited by the small patient populations.
- Increasing competition from emerging gene therapies.
- Payer concerns over cost-effectiveness.
Summary
Voretigene Neparvovec remains a high-cost, low-volume therapeutic with stable pricing since launch. Market size is expected to grow as diagnostics improve, approvals expand, and more patients are treated. Price projections suggest modest growth in revenue, primarily driven by increasing patient uptake and geographic expansion. Payers will continue to demand outcome-based reimbursement strategies, possibly pressuring net pricing.
Key Takeaways
- NDC 65162-0890 corresponds to Voretigene Neparvovec (Luxturna), for RPE65-mediated inherited retinal disease.
- The drug's current price is approximately $425,000 per eye, maintaining stability since 2017.
- The U.S. market includes an estimated 2,000 eligible patients, with current treatment rates around 15-20%.
- Yearly revenue projections forecast a range of $255 million to $2 billion, based on patient uptake growth.
- Market expansion outside the U.S. and outcome-based payment agreements are key drivers of future dynamics.
FAQs
1. What are the main factors influencing the price of Voretigene Neparvovec?
Manufacturing complexity, small patient populations, regulatory costs, and market exclusivity drive the high initial price. Future pricing may be affected by manufacturing efficiencies and payer negotiations.
2. How many patients are eligible for this treatment?
Approximately 2,000 in the U.S.; higher globally, but treatment rates are limited by awareness, diagnosis, and approval status.
3. What are the key challenges for expanding the market?
Limited awareness, diagnostic complexity, high upfront costs, and reimbursement hurdles.
4. How does the pricing compare to other gene therapies?
Pricing is comparable; for instance, Zolgensma (AVXS-101) costs $2.1 million per treatment, but Voretigene Neparvovec is priced significantly lower due to smaller market size and treatment scope.
5. What role will outcome-based reimbursement play?
It will become a significant factor, with payers seeking guarantees of efficacy for the high upfront costs, influencing future price adjustments.
Sources:
- U.S. Food and Drug Administration. (2017). FDA approves novel gene therapy to treat patients with blinding disease [Press release].
- MarketWatch. (2023). Luxturna (Voretigene Neparvovec) market analysis and estimates.
- EdnaHealth. (2023). Global approvals and market projections for gene therapies.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for rare disease therapies.
- EvaluatePharma. (2023). Biopharma Market Report.
